14.26

0.21% 0.03

After Hours: 14.26

Edgewise Therapeutics Inc (EWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Edgewise Therapeutics Inc stock is traded at $14.26, with a volume of 531.83K. It is up +0.21% in the last 24 hours and up +8.77% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Previous Close:

$14.23

Open:

$14.09

24h Volume:

531.83K

Relative Volume:

0.60

Market Cap:

$1.50B

Revenue:

Net Income/Loss:

$-115.88M

P/E Ratio:

-9.219

EPS:

-1.5468

Net Cash Flow:

$-104.72M

1W Performance:

-2.53%

1M Performance:

+8.77%

6M Performance:

-49.11%

1Y Performance:

-16.27%

1-Day Range:

$14.08

$14.79

1-Week Range:

$13.78

$15.33

52-Week Range:

$10.60

$38.12

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name

Edgewise Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

720-262-7002

Address

1715 38TH ST, BOULDER

Employee

117

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

EWTX's Discussions on Twitter

Compare EWTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EWTX Edgewise Therapeutics Inc	14.26	1.50B	0	-115.88M	-104.72M	-1.5468
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Initiated	Raymond James	Strong Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Apr-30-25	Initiated	Guggenheim	Buy
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Jan-22-25	Initiated	Stifel	Hold
Nov-22-24	Initiated	Evercore ISI	Outperform
Mar-07-24	Initiated	Piper Sandler	Overweight
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell
Apr-13-22	Initiated	RBC Capital Mkts	Outperform
Jan-28-22	Initiated	Goldman	Neutral

View All

Edgewise Therapeutics Inc Stock (EWTX) Latest News

12:09 PM

Raymond James Initiates Strong Buy on Edgewise Therapeutics (EWTX) with $46 PT, Cites EDG-7500 Potential for HCM - Insider Monkey

12:09 PM

Jul 31, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 8.3%Time to Buy? - MarketBeat

Jul 31, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Edgewise Therapeutics, Inc. (EWTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 31, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener

Jul 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - PR Newswire

Jul 31, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by Analysts at Raymond James Financial - MarketBeat

Jul 31, 2025

Heatmap analysis for Edgewise Therapeutics Inc. and competitorsSmart Stock Forecast Using AI Algorithms - Newser

Jul 31, 2025

Is Edgewise Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Sector Based Breakout Stock Forecast - Newser

Jul 31, 2025

How Edgewise Therapeutics Inc. stock performs during market volatilitySector Rotation Strategy for Smart Traders - Newser

Jul 31, 2025

Published on: 2025-07-31 00:37:16 - Newser

Jul 31, 2025

Visualizing Edgewise Therapeutics Inc. stock with heatmapsFree Low Risk Swing Trade Opportunity List - Newser

Jul 31, 2025

Jul 30, 2025

How sentiment analysis helps forecast Edgewise Therapeutics Inc.Free Weekly Top Gainers Forecast Watchlist - Newser

Jul 30, 2025

Raymond James Initiates Edgewise Therapeutics at Strong Buy - MarketScreener

Jul 30, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Jul 30, 2025

37,591 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat

Jul 30, 2025

When is the best time to buy Edgewise Therapeutics Inc. stockEarnings Report Summary with Market Impact - Newser

Jul 30, 2025

What makes Edgewise Therapeutics Inc. stock price move sharplySector Rotation Outlook With Historical Summary - Newser

Jul 30, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Jul 30, 2025

Jul 29, 2025

Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada

Jul 29, 2025

Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating - Investing.com

Jul 29, 2025